A car-t cell therapy has received an fda breakthrough therapy designation. The therapy is intended for the treatment of aggressive t-cell cancers, including relapsed or refrractory t cell acute lymphoblastic leukemia and t cell lymphoblastic lymphoma. However, it is unclear which specific car-t cell therapy has received the designation, as multiple therapies are mentioned across different reports.